Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma

作者：Yanamoto Souichi^*; Umeda Masahiro; Kioi Mitomu; Kirita Tadaaki; Yamashita Tetsuro; Hiratsuka Hiroyoshi; Yokoo Satoshi; Tanzawa Hideki; Uzawa Narikazu; Shibahara Takahiko; Ota Yoshihide; Kurita Hiroshi; Okura Masaya; Hamakawa Hiroyuki; Kusukawa Jingo; Tohnai Iwai

来源：Cancer Chemotherapy and Pharmacology, 2018, 81(3): 549-554.

DOI：10.1007/s00280-018-3531-x

• Oral cancer
• Recurrence
• Metastasis
• Cetuximab
• Retrospective study

The purpose of this study was to assess the efficacy and safety of cetuximab plus platinum-based chemotherapy for patients specifically diagnosed with recurrent or metastatic oral squamous cell carcinoma (OSCC).
We conducted a multicenter retrospective observational study of patients who underwent first-line cetuximab plus platinum-based chemotherapy between December 2012 and June 2015. 65 patients received weekly cetuximab (week 1, 400 mg/m(2); subsequent weeks, 250 mg/m(2)) plus a maximum of six 3-weekly cycles of cisplatin (80 or 100 mg/m(2), day 1) or carboplatin (at an area under the curve of 5 mg/mL/min as a 1-h intravenous infusion on day 1) and 5-fluorouracil (800 or 1000 mg/m(2)/day, days 1-4). Patients with stable disease who received cetuximab plus platinum-based chemotherapy continued to receive cetuximab until disease progression or unacceptable toxicities, whichever occurred first.
The median follow-up was 10.5 (range 1.2-34.2) months. The best overall response and the disease control rates were 46.2 and 67.7%, respectively. The median overall survival and progression-free survival rates were 12.1 and 7.8 months, respectively. The most common grades 3-4 adverse events were skin rash (9.2%) followed by leukopenia (6.2%). None of the adverse events were fatal.
The results of our multicenter retrospective study, which was the largest of its kind to date, suggest that first-line cetuximab plus platinum-based chemotherapy is suitable and well-tolerated for the systemic therapy of recurrent or metastatic OSCC.

• 出版日期2018-3